RYAN Stock Analysis: Ryan Specialty Holdings | NYSE
Insurance Brokers | NYSE, USA | Market Cap: 9.700m USD | 12M Return: -33.5% | US78351F1075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 79.5M
EPS Trend: 97.6%
Qual. Beats: 2
Rev. Trend: 99.6%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ryan Specialty Group Holdings, Inc. (NYSE: RYAN) is a specialty insurance services provider that operates as both a wholesale broker and a managing underwriter/program administrator with delegated authority from insurance carriers. Founded in 2010 and headquartered in Chicago, Illinois, the company offers distribution, underwriting, product development, administration, and risk management services to insurance brokers, agents, and carriers.
The company serves a diverse client base across commercial, industrial, institutional, individual, and government sectors, with operations spanning the United States, Canada, the United Kingdom, the rest of Europe, India, Singapore, and other international markets. Ryan Specialty went public on July 22, 2021, and is classified within the Financials sector under the GICS Insurance Brokers sub-industry.
As a wholesale broker and managing general underwriter, Ryan Specialty occupies an intermediary position in the insurance value chain, connecting retail brokers with insurance carriers and assuming underwriting authority on behalf of those carriers. This delegated authority model allows the company to quote, bind, and service policies in the carriers name, which is a defining feature of the specialty insurance distribution sector.
- Specialty insurance pricing strength fuels organic revenue growth
- Bolt-on acquisitions accelerate international specialty expansion
- Reinsurance hard market lifts delegated underwriting margins
| Net Income: 188.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.61 > 1.0 |
| NWC/Revenue: 36.88% < 20% (prev 164.8%; Δ -127.9% < -1%) |
| CFO/TA 0.05 > 3% & CFO 558.5m > Net Income 188.0m |
| Net Debt (3.84b) to EBITDA (789.7m): 4.86 < 3 |
| Current Ratio: 1.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (131.3m) vs 12m ago -52.10% < -2% |
| Gross Margin: 81.13% > 18% (prev 40.27%; Δ 40.87% > 0.5%) |
| Asset Turnover: 28.48% > 50% (prev 26.48%; Δ 2.01% > 0%) |
| Interest Coverage Ratio: 2.29 > 6 (EBIT TTM 504.5m / Interest Expense TTM 219.9m) |
| A: 0.10 (Total Current Assets 6.64b - Total Current Liabilities 5.46b) / Total Assets 12.0b |
| B: 0.01 (Retained Earnings 145.3m / Total Assets 12.0b) |
| C: 0.04 (EBIT TTM 504.5m / Avg Total Assets 11.3b) |
| D: 0.05 (Book Value of Equity 509.4m / Total Liabilities 11.0b) |
| Altman-Z'' = 1.04 = BB |
| DSRI: 0.12 (Receivables 697.6m/5.03b, Revenue 3.22b/2.81b) |
| GMI: 0.50 (GM 40.27% / 81.13%) |
| AQI: 0.89 (AQ_t 0.43 / AQ_t-1 0.48) |
| SGI: 1.14 (Revenue 3.22b / 2.81b) |
| TATA: -0.03 (NI 188.0m - CFO 558.5m) / TA 12.0b) |
| Beneish M = -4.17 (Cap -4..+1) = AAA |
As of October 01, 2026, the stock is trading at USD 37.00 with a total of 1,662,171 shares traded. Over the past week, the price has changed by +2.29%, over one month by -12.28%, over three months by -1.71% and over the past year by -33.52%.
Current recommended Stop Loss: 34.90 (which is 5.7% or 1.3 ATR below the current price).
Ryan Specialty Holdings has received a consensus analysts rating of 3.92. Therefore, it is recommended to buy RYAN.
- StrongBuy: 4
- Buy: 5
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 50.5 | 36.6% |
P/E Trailing = 51.1486
P/E Forward = 14.6413
P/S = 3.0664
P/B = 8.6679
Revenue TTM = 3.22b USD
EBIT TTM = 504.5m USD
EBITDA TTM = 789.7m USD
Long Term Debt = 3.57b USD (from longTermDebt, last quarter)
Short Term Debt = 90.4m USD (from shortTermDebt, last quarter)
Debt = 3.98b USD (from shortLongTermDebtTotal, last quarter) + Leases 174.4m
Net Debt = 3.84b USD (calculated: Debt 3.98b - CCE 140.1m)
Enterprise Value = 13.5b USD (9.70b + Debt 3.98b - CCE 140.1m)
Interest Coverage Ratio = 2.29 (Ebit TTM 504.5m / Interest Expense TTM 219.9m)
EV/FCF = 26.33x (Enterprise Value 13.5b / FCF TTM 514.2m)
FCF Yield = 3.80% (FCF TTM 514.2m / Enterprise Value 13.5b)
FCF Margin = 15.98% (FCF TTM 514.2m / Revenue TTM 3.22b)
Net Margin = 5.84% (Net Income TTM 188.0m / Revenue TTM 3.22b)
Gross Margin = 81.13% ((Revenue TTM 3.22b - Cost of Revenue TTM 607.1m) / Revenue TTM)
Gross Margin QoQ = 92.52% (prev 91.27%)
Tobins Q-Ratio = 1.13 (Enterprise Value 13.5b / Total Assets 12.0b)
Interest Expense / Debt = 5.52% (Interest Expense 219.9m / Debt 3.98b)
Taxrate = 13.97% (39.4m / 282.2m)
NOPAT = 434.0m (EBIT 504.5m * (1 - 13.97%))
Current Ratio = 1.15 (Total Current Assets 6.64b / Total Current Liabilities 5.80b)
Debt / Equity = 7.82 (Debt 3.98b / totalStockholderEquity, last quarter 509.4m)
Debt / EBITDA = 4.86 (Net Debt 3.84b / EBITDA 789.7m)
Debt / FCF = 7.47 (Net Debt 3.84b / FCF TTM 514.2m)
Total Stockholder Equity = 606.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.66% (Net Income 188.0m / Total Assets 12.0b)
RoE = 31.03% (Net Income TTM 188.0m / Total Stockholder Equity 606.0m)
RoCE = 12.08% (EBIT 504.5m / Capital Employed (Equity 606.0m + L.T.Debt 3.57b))
RoIC = 3.67% (NOPAT 434.0m / Invested Capital 11.8b)
WACC = 4.89% (E(9.70b)/V(13.7b) * Re(4.95%) + D(3.98b)/V(13.7b) * Rd(5.52%) * (1-Tc(0.14)))
Discount Rate = 4.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -54.49 | Cagr: -27.40%
[DCF] Terminal Value 77.97% ; FCFF base≈465.3m ; Y1≈533.4m ; Y5≈785.0m
[DCF] Fair Price = 65.30 (EV 11.8b - Net Debt 3.84b = Equity 7.97b / Shares 122.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.57 | EPS CAGR: 19.06% | SUE: 4.0 | # QB: 2
Revenue Correlation: 99.63 | Revenue CAGR: 20.51% | SUE: 2.91 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.49 | Chg30d=-3.99% | Revisions=-36% | Analysts=19
EPS current Year (2026-12-31): EPS=2.17 | Chg30d=+5.20% | Revisions=+86% | GrowthEPS=+10.6% | GrowthRev=+7.8%
EPS next Year (2027-12-31): EPS=2.42 | Chg30d=-0.17% | Revisions=+65% | GrowthEPS=+11.6% | GrowthRev=+7.4%
[Analyst] Revisions Ratio: +53% (up=36, down=10)